Background Guselkumab is proven effective and safe for moderate-to-severe plaque psoriasis, but its safety in patients with comorbid infectious diseases and malignancies has been less studied.Objectives The EARLY study was a real-world longitudinal study designed to assess clinical outcomes and long-term safety of guselkumab in patients with psoriasis who also had chronic infections, malignancies or heart disease.Methods A cohort of 1024 patients with moderate-to-severe psoriasis treated with guselkumab was evaluated for the presence of chronic infection [hepatitis B virus (HBV) and hepatitis C virus (HCV), tuberculosis and HIV] and cancer. Subgroup analysis was also performed in patients with heart disease. Patients with cancer were categorized into the precedent cancer (PC) group, with diagnoses made before the study, and the intercurrent cancer (IC) group, with diagnosis occurring during the study. Stratification was also performed based on oncological risk (high-risk and low-risk groups), according to 2022 Italian guidelines.Results Among 1024 patients, 7.5% (n = 77) had HBV, 7.4% (n = 76) had latent tuberculosis infection, 2.7% (n = 28) had HCV, and 0.8% (n = 8) were HIV-positive. In these patients (n = 189), no reactivation of infectious diseases was observed during a mean follow-up period of 128.5 (SD 81.2) weeks. In the 65 patients with cancer (6.3% of the cohort), 78% (n = 51) were in the PC group and 22% (n = 14) were in the IC group. Time from cancer diagnosis to guselkumab initiation averaged 11.8 (SD 15.5) months in patients at high risk and 113.3 (SD 58.5) months in patients at low risk. In patients with heart disease, mean follow-up was 121.0 (SD 76.9) weeks.Conclusions This longitudinal real-world study demonstrates the long-term safety of guselkumab in patients with psoriasis who had chronic infections, cancer or heart disease. Stratification by oncological risk provided valuable insights for therapeutic management.This real-world study evaluated the safety of guselkumab in 1024 patients with moderate-to-severe psoriasis who also had chronic infections, cancer or heart disease. No viral reactivation occurred in patients with infections, and guselkumab was found to be safe for patients with cancer or heart disease. The findings provide valuable insights for managing psoriasis treatment in patients with these comorbidities.
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY Study
Raimondo, Annunziata;Lembo, Serena;
2025
Abstract
Background Guselkumab is proven effective and safe for moderate-to-severe plaque psoriasis, but its safety in patients with comorbid infectious diseases and malignancies has been less studied.Objectives The EARLY study was a real-world longitudinal study designed to assess clinical outcomes and long-term safety of guselkumab in patients with psoriasis who also had chronic infections, malignancies or heart disease.Methods A cohort of 1024 patients with moderate-to-severe psoriasis treated with guselkumab was evaluated for the presence of chronic infection [hepatitis B virus (HBV) and hepatitis C virus (HCV), tuberculosis and HIV] and cancer. Subgroup analysis was also performed in patients with heart disease. Patients with cancer were categorized into the precedent cancer (PC) group, with diagnoses made before the study, and the intercurrent cancer (IC) group, with diagnosis occurring during the study. Stratification was also performed based on oncological risk (high-risk and low-risk groups), according to 2022 Italian guidelines.Results Among 1024 patients, 7.5% (n = 77) had HBV, 7.4% (n = 76) had latent tuberculosis infection, 2.7% (n = 28) had HCV, and 0.8% (n = 8) were HIV-positive. In these patients (n = 189), no reactivation of infectious diseases was observed during a mean follow-up period of 128.5 (SD 81.2) weeks. In the 65 patients with cancer (6.3% of the cohort), 78% (n = 51) were in the PC group and 22% (n = 14) were in the IC group. Time from cancer diagnosis to guselkumab initiation averaged 11.8 (SD 15.5) months in patients at high risk and 113.3 (SD 58.5) months in patients at low risk. In patients with heart disease, mean follow-up was 121.0 (SD 76.9) weeks.Conclusions This longitudinal real-world study demonstrates the long-term safety of guselkumab in patients with psoriasis who had chronic infections, cancer or heart disease. Stratification by oncological risk provided valuable insights for therapeutic management.This real-world study evaluated the safety of guselkumab in 1024 patients with moderate-to-severe psoriasis who also had chronic infections, cancer or heart disease. No viral reactivation occurred in patients with infections, and guselkumab was found to be safe for patients with cancer or heart disease. The findings provide valuable insights for managing psoriasis treatment in patients with these comorbidities.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
